Four categories that rule it out

Knowing quickly whether this treatment is likely to apply to you is the most useful thing this article can offer. ChondroFiller™ is an injectable collagen scaffold that works by creating a matrix for the body's own repair cells to migrate into — which means the biology of the joint, and of the patient receiving it, matters a great deal to the outcome.

Most exclusions fall into four broad areas: a known allergy to the material the scaffold is made from; active infection or systemic inflammatory disease that would undermine the repair environment; structural joint damage that goes beyond what an injectable scaffold can meaningfully address; and biomechanical or compliance factors that reduce how long any repair is likely to last.

A published post-market series of more than 19,000 cases records a very low adverse-event rate — a figure that reflects how the treatment performs in carefully selected patients, not a guarantee that it is suitable for everyone.

This article covers the outpatient, ultrasound-guided injection pathway specifically; a separate surgical implantation route exists and carries its own, partly different, anatomical criteria.

Allergy to collagen or murine-derived proteins

ChondroFiller™ is manufactured from Type I collagen derived from murine sources — meaning the raw material comes from mice rather than cattle or synthetic compounds. For the vast majority of patients this poses no problem, but for anyone with a confirmed allergy to murine-derived proteins or to Type I collagen itself, it is an absolute contraindication. No dose adjustment, antihistamine pre-treatment, or alternative preparation changes this: the scaffold's ability to support tissue repair depends entirely on its collagen composition, and that composition cannot be separated out or substituted.

Before proceeding, a clinician will take a careful allergy history, asking about reactions to animal-derived products or previous exposure to collagen-based medical devices. Where the history is uncertain, a sensitivity check may be carried out. The consultation is the right moment to raise any known or suspected animal-protein sensitivities, however minor they seem.

This exclusion is uncommon in practice — most patients have no relevant allergy history — but it is non-negotiable when it does apply. Anyone for whom it rules out ChondroFiller™ will need to explore alternative injectable or surgical pathways at assessment.

Active infection, inflammatory joint disease, and systemic conditions

Two broad themes define this tier of exclusions: conditions that create a hostile environment within the joint itself, and systemic health factors that compromise the body's capacity to support scaffold-mediated repair.

Infection and inflammatory joint disease

Any active infection — whether localised in or around the joint or present systemically — rules out the procedure until it is resolved. Placing a biologic matrix into an infected environment carries significant clinical risk; the standard approach is to treat the infection fully and reassess once the joint environment is clear.

Active inflammatory arthropathies — including rheumatoid arthritis, psoriatic arthritis, and gout — are excluded on mechanism-based rather than precautionary grounds. Immune-mediated inflammation characteristic of these conditions can degrade the collagen scaffold before the repair process gains any foothold. Patients with a history of inflammatory arthritis whose disease is currently controlled should raise this at consultation; active flare and stable remission represent meaningfully different biological environments, and the treating clinician will assess the picture accordingly.

Systemic health conditions

Significant immunosuppression is relevant because the scaffold depends on the body's own progenitor cells migrating into the matrix — a process that requires an adequate immune response. The degree and underlying cause matter, making this a point to discuss openly at assessment rather than an automatic bar for everyone on immunomodulatory therapy.

Uncontrolled bleeding disorders and active malignancy are also listed exclusions. Pregnancy is excluded on precautionary grounds — no specific safety data exist for this group — and breastfeeding is treated similarly; the standard approach is to wait until both have ceased before revisiting candidacy.

What advanced joint damage means for suitability

Cartilage damage exists on a spectrum, and where a patient sits on that spectrum affects not just whether ChondroFiller™ is appropriate, but which treatment pathway applies.

How contained the damage is changes the picture

The scaffold performs best when there is a focal area of cartilage loss — a defined defect — with intact, healthy cartilage around its borders. Those healthy borders provide the biological anchoring environment the collagen matrix needs to support tissue repair. Where damage is very extensive, reaching deep into the layer of bone beneath the cartilage (the subchondral bone), the structural platform for integration is compromised and the injection is unlikely to achieve meaningful repair.

Injection and surgical pathways carry different thresholds

ChondroFiller™ is also available through a separate surgical implantation route — a different procedure altogether from the outpatient, ultrasound-guided injection this article principally addresses. That surgical pathway requires a contained focal defect with defined, stable cartilage borders. Patients with advanced or generalised osteoarthritis — broadly, severe end-stage joint-space loss on imaging (sometimes graded as Kellgren-Lawrence Grade IV in the knee, or Tönnis grade above 2 in the hip, referring to the degree of joint-space narrowing visible on X-ray) — typically cannot meet that containment criterion. For the surgical pathway, this is a disqualifying factor.

For the outpatient injection, however, the anatomical threshold is wider. Evidence suggests the injectable scaffold can function as a supportive, load-absorbing layer across more diffuse joint wear — including moderate-to-severe OA — where the goal shifts from focal regeneration towards joint support and symptom relief. Advanced OA does not automatically rule out the injection.

The point at which even the injection becomes unsuitable — multi-compartmental bone-on-bone destruction across the whole joint — is a structural limit for both routes. Between these poles, there is no single published threshold that settles the question; MRI assessment at consultation is how the boundary is determined for each patient individually.

Mechanical joint problems and realistic expectations

Joints work as systems. When ligament instability, significant malalignment, or an active meniscal problem is driving cartilage wear, treating the cartilage surface alone leaves the mechanical cause unaddressed. ChondroFiller™ can support the damaged area, but it does not correct joint mechanics — and uncorrected mechanics reduce how long the repair environment holds. These factors are relative contraindications: they call for clinical judgement about sequencing rather than a blanket refusal, and in several cases addressing the underlying mechanical issue first is precisely what makes a later injection more durable.

Compliance with post-procedure guidance is a practical consideration alongside the clinical ones. The collagen scaffold requires a protected loading environment in the days following injection while the matrix establishes in the joint. Patients who cannot follow activity-modification and weight-bearing advice during this window — whether due to work demands, mobility constraints, or other personal circumstances — may not be able to provide the conditions the device needs.

Expectations are part of patient selection too. Published data support symptom improvement and scaffold integration in appropriately chosen cases, but evidence does not indicate that full cartilage regeneration is guaranteed, nor that every patient returns to previous athletic performance. Where a patient expects certainty of outcome, open counselling at assessment helps establish whether the realistic range of results aligns with their goals.

All of these factors sit in the relative rather than absolute column. Each requires a treating clinician to weigh the individual picture — which is why a thorough pre-procedure assessment covers not just the joint itself, but the mechanics around it and the patient's ability to commit to recovery.

How suitability is assessed before injection

MRI of the affected joint is the primary decision tool at this stage — it characterises defect size, depth, subchondral involvement, and the state of surrounding cartilage in ways that plain X-ray alone cannot. A Kellgren-Lawrence or Tönnis grade tells the clinician where a patient sits on a spectrum; MRI reveals whether the tissue environment would actually support scaffold integration.

A clinical consultation brings imaging together with a full medical history: allergy status, systemic conditions, inflammatory markers, current medications, and a candid conversation about recovery compliance and what the patient realistically expects from treatment. For patients who want to begin that process, an online suitability assessment is available through the AMSK platform as a practical first step before a formal appointment.

The exclusion criteria described across this article are clinical principles, not a rigid checklist that yields a binary answer in every case. Grey zones are common: a patient with well-controlled inflammatory disease, or one whose mechanical instability has already been addressed, may sit at the edge of more than one category. In those cases the outcome rests on clinical judgement and shared decision-making — not on whether a single criterion applies.

Patients who do not qualify for ChondroFiller™ injection are not without options. Depending on the clinical picture, alternatives include viscosupplementation with hyaluronic acid for symptom management, platelet-rich plasma as a biologic support pathway, or — where structural disease is more advanced — surgical joint-preservation options or, ultimately, joint replacement. Identifying which pathway fits a given patient is precisely what a thorough consultation is designed to establish.